![](/img/cover-not-exists.png)
PCN46 COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY: A SENSITIVITY ANALYSIS ON THE ECOG STATUS
D Heigener, HG Bischoff, K Banz, S WalzerVolume:
12
Year:
2009
Language:
english
DOI:
10.1016/s1098-3015(10)74297-2
File:
PDF, 73 KB
english, 2009